Conference Proceedings
LURASIDONE FOR THE TREATMENT OF MAJOR DEPRESSIVE DISORDER WITH MIXED FEATURES: RESULTS OF A 12-WEEK OPEN-LABEL EXTENSION STUDY
SM Stahl, A Pikalov, M Tocco, Y Mao, A Loebel, M Hopwood
AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY | SAGE PUBLICATIONS LTD | Published : 2019
Grants
Funding Acknowledgements
Funded by Sunovion Pharmaceuticals Inc., Sumitomo Dainippon Pharma and Servier Australia